scholarly journals Elevated Serum Amyloid A Is Associated With Cognitive Impairment in Ischemic Stroke Patients

2022 ◽  
Vol 12 ◽  
Author(s):  
Yun Zhang ◽  
Yue Feng ◽  
Jiacai Zuo ◽  
Jian Shi ◽  
Shanshan Zhang ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Cognitive Impairment ◽  
Cognitive Assessment ◽  
Serum Amyloid A ◽  
National Institutes Of Health ◽  
Serum Amyloid ◽  
Montreal Cognitive Assessment ◽  
Enzyme Linked Immunosorbent Assay ◽  
Assessment Score ◽  
Amyloid A

Background and PurposeThe impact of serum amyloid A on cognitive impairment after ischemic stroke is unclear. We aimed to investigate the association between serum amyloid A (SAA) levels and post-stroke cognitive impairment (PSCI) at 3 months after ischemic stroke.MethodsOne hundred and ninety-eight patients were enrolled prospectively from June 2020 to April 2021. The SAA concentrations were measured using a commercially available enzyme-linked immunosorbent assay kit after admission. Cognitive function was assessed using the Montreal Cognitive Assessment score at 3 months after the symptom onset. We defined a Montreal Cognitive Assessment score <25 as cognitive impairment.ResultsDuring 3-month follow-up, 80 patients (40.4%) were diagnosed as having PSCI. As compared with patients with cognitively normal ischemic stroke, those with PSCI were older, more likely to have diabetes and white matter lesions, and had a higher baseline National Institutes of Health stroke score and SAA levels. After adjustment for age, the National Institutes of Health stroke score and other covariates, the OR for the highest quartile of SAA compared with the lowest quartile was 5.72 (95% CI, 2.17–15.04, P = 0.001) for PSCI. Also, ordinal logistic regression analysis showed that higher SAA concentrations were associated with increased risk of PSCI severity (OR, 4.31; 95% CI, 1.81–10.33, P = 0.001). Similar results were found when the SAA levels were analyzed as a continuous variable.ConclusionsThis present study demonstrated that increased SAA levels might be associated with PSCI at 3 months after ischemic stroke.

scholarly journals Subclinical Cognitive Impairment and Listing for Kidney Transplantation

2019 ◽  
Vol 14 (4) ◽  
pp. 567-575 ◽  
Author(s):  
Aditi Gupta ◽  
Robert N. Montgomery ◽  
Victor Bedros ◽  
John Lesko ◽  
Jonathan D. Mahnken ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Kidney Transplant ◽  
Cognitive Assessment ◽  
Proportional Hazards Model ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Montreal Cognitive Assessment ◽  
Rank Test ◽  
Assessment Score ◽  
Lower Likelihood

Background and objectivesCognitive impairment is common in patients with kidney disease and can affect physicians’ perception and/or patients’ ability to complete the pretransplant evaluation. We examined whether cognitive impairment influences the likelihood for transplant listing and whether patients with cognitive impairment take longer to be listed.Design, setting, participants, & measurementsWe conducted a single-center longitudinal cohort study. Patients presenting for their index kidney transplant evaluation were screened for cognitive impairment using the Montreal Cognitive Assessment. A score <26 indicated cognitive impairment. The transplant selection committee was blinded to the scores. Kaplan–Meier analysis assessed time to active listing by level of cognition. A Cox proportional hazards model that included age, sex, race/ethnicity, smoking, coronary artery disease, and diabetes was constructed to evaluate the association between Montreal Cognitive Assessment score and listing for transplant.ResultsIn total, 349 patients who underwent Montreal Cognitive Assessment testing at their initial visit were included in the analysis. Patients with cognitive impairment were more likely to be older, black, and smokers. The time to listing in patients with cognitive impairment was longer than the time to listing in those with no cognitive impairment (median time, 10.6 versus 6.3 months; log rank test P=0.01). Cognitive impairment was independently associated with a lower likelihood of being listed for transplant (hazard ratio, 0.93 per unit lower Montreal Cognitive Assessment score; 95% confidence interval, 0.88 to 0.99; P=0.02). A lower proportion of patients with cognitive impairment were listed compared with patients without cognitive impairment at 1 month (2% versus 11%), 6 months (17% versus 37%), and 1 year (23% versus 41%), (P<0.001 for all).ConclusionsCognitive impairment is associated with a lower likelihood of being listed for kidney transplant, and is associated with longer time to transplant listing.

scholarly journals Serum Amyloid A Protein as a Potential Biomarker for Severity and Acute Outcome in Traumatic Brain Injury

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Evan Wicker ◽  
Leah Benton ◽  
Kershina George ◽  
William Furlow ◽  
Sonia Villapol
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Serum Amyloid A ◽  
Protein Detection ◽  
Serum Amyloid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Lesion Volume ◽  
Amyloid A ◽  
Potential Biomarker ◽  
Serum Amyloid A Protein

Traumatic brain injury (TBI) causes a wide variety of neuroinflammatory events. These neuroinflammatory events depend, to a greater extent, on the severity of the damage. Our previous studies have shown that the liver produces serum amyloid A (SAA) at high levels in the initial hours after controlled cortical impact (CCI) injury in mice. Clinical studies have reported detectable SAA in the plasma of brain injury patients, but it is not clear if SAA levels depend on TBI severity. To evaluate this question, we performed a mild to severe CCI injury in wild-type mice. We collected blood samples and brains at 1, 3, and 7 days after injury for protein detection by western blotting, enzyme-linked immunosorbent assay, or immunohistochemical analysis. Our results showed that severe CCI injury compared to mild CCI injury or sham mice caused an increased neuronal death, larger lesion volume, increased microglia/macrophage density, and augmented neutrophil infiltration. Furthermore, we found that the serum levels of SAA protein ascended in the blood in correlation with high neuroinflammatory and neurodegenerative responses. Altogether, these results suggest that serum SAA may be a novel neuroinflammation-based, and severity-dependent, biomarker for acute TBI.

Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnosis confirmation

2009 ◽  
Vol 205 (2) ◽  
pp. 561-567 ◽  
Author(s):  
David Brea ◽  
Tomás Sobrino ◽  
Miguel Blanco ◽  
Máximo Fraga ◽  
Jesús Agulla ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Serum Amyloid A ◽  
Serum Amyloid ◽  
Amyloid A ◽  
Stroke Diagnosis

scholarly journals FRI0569 SERUM AMYLOID A: ASSESSMENT OF REFERENCE VALUE AND COMPARISON OF SERUM CONCENTRATION IN HEALTHY SUBJECTS AND PATIENTS WITH BEHÇET SYNDROME

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 887.3-887
Author(s):  
T. Carbone ◽  
M. C. Padula ◽  
V. Pafundi ◽  
C. Schievano ◽  
N. Lascaro ◽  
...  
Keyword(s):  
Serum Concentration ◽  
Serum Amyloid A ◽  
Laboratory Medicine ◽  
Serum Amyloid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Population ◽  
Significant Information ◽  
Behçet Syndrome ◽  
Amyloid A ◽  
Behcet Syndrome

Background:Serum amyloid A (SAA) is a family of acute-phase reactants. The rise of SAA concentration in blood circulation is a clinical marker of active inflammation in several auto-inflammatory diseases, including Behçet syndrome (BS). Despite its practical and analytical advantages, SAA measurement by ELISA has been mainly used as a research tool rather than for the routine laboratory testing due to the lack of a robust reference data in the literature.Objectives:Using the recommended procedures of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), we aimed to develop the SAA reference interval for a well-defined Italian healthy population (HC). Secondly, we compared the SAA serum concentration between HC and patients with BS.Methods:Sera specimens were collected from adult healthy blood donors after rule out the exclusion criteria (inflammatory disorders, ongoing infections, pregnancy and breastfeeding, obesity, using oral contraceptives, use of any medication, or consumed of alcohol), and from unselected BS patients fulfilling the International Study Group (ISG) classification criteria. Serum SAA concentrations were detected and quantified with a commercial solid phase sandwich enzyme-linked immunosorbent assay (Human SAA ELISA kit, IBL International GmbH, Hamburg, Germany) used on automated analyzer (Immunomat, SERION Diagnostic, Alifax, Polverara (PD), Italy) according to the manufacturer’s protocol. Statistical analysis and data normalization of HC SAA values were carried out to determine the reference cut off. In the second step of the study, HC and BS patients were stratified in two groups according to the cut-off value.Results:We recruited 141 HC (84 M and 57 F; mean age, 44.5±13.2 years) and 63 BS patients (39 M and 24 F mean age, 45.3±13.2 years) assayed for SAA. The reference cut-off was calculated as 225 ng/ml. No statistically significant differences were found between males and females when SAA means were compared, suggesting that not gender-partitioned reference range is recommended for this analyte. After the stratification according to the cut-off value (group 1: < 225 ng/ml and group 2: > 225 ng/ml), we found 53/63 (84.1%) BS patients and 133/141 (94.3%) HC with concentration less than cut-off value, respectively. We identified 10/63 (15.9%) BS patients and 8/141 (5.7%) HC within the second group. The difference was statistically significant (p=0.0177; OR: 3.14, 95% CI: 1.17-3.38).Conclusion:This study allowed to define a widely accepted reference cut-off for the SAA detected by ELISA, responding to an unmet need of laboratory medicine. We found a statistically significant higher frequency of BS patients compared with HC when SAA values is higher than cut-off (225 ng/ml). This preliminary data could add significant information for better clarify the role of SAA as biomarker of inflammation and in guidance of clinical practice. Further studies will be required to stratify SAA values in relation to disease activity of BS.Disclosure of Interests:Teresa Carbone: None declared, Maria Carmela Padula: None declared, Vito Pafundi: None declared, Carlo Schievano: None declared, Nancy Lascaro: None declared, Angela Padula: None declared, Pietro Leccese: None declared, Salvatore D’Angelo Consultant of: AbbVie, Biogen, BMS, Celgene, Eli Lilly, MSD, Novartis, and UCB, Speakers bureau: AbbVie, BMS, Celgene, Eli Lilly, Novartis, Pfizer, and Sanofi

Evaluation of goose serum amyloid a acute phase response by enzyme-linked immunosorbent assay

2007 ◽  
Vol 55 (3) ◽  
pp. 349-357 ◽  
Author(s):  
Beáta Kovács ◽  
Mathilda Toussaint ◽  
E. Gruys ◽  
Ibolya Fábián ◽  
L. Szilágyi ◽  
...  
Keyword(s):  
Acute Phase ◽  
Pasteurella Multocida ◽  
Serum Amyloid A ◽  
Serum Amyloid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Common Disease ◽  
Post Inoculation ◽  
Secondary Amyloidosis ◽  
Phase Reaction ◽  
Amyloid A

Serum amyloid A (SAA) is of interest as the circulating precursor of amyloid A protein, the fibrillar component of AA (secondary) amyloid deposits, and also as an extremely sensitive and rapid major acute phase protein. Serum concentrations of acute phase proteins (APPs) provide valuable information about the diagnosis and prognosis of various diseases, and thus the relevance of APPs for monitoring the health status of domestic animals is widely accepted. More importantly, the measurement of SAA concentration assists in assessing the prognosis in secondary amyloidosis, which is a common disease of geese, affecting an increasing number of animals. In the present study we introduce a highly sensitive goose-specific ELISA method for measuring SAA concentration in goose serum or plasma samples. Samples were taken from geese of the Landes Grey and Hungarian White breeds, which were stimulated for an acute phase reaction by administration of a commercially available fowl cholera vaccine containing inactivated Pasteurella multocida . Strong and characteristically rapid acute phase responses were measured in both breeds, peaking at approximately 24 h after inoculation. The maximum SAA concentration was 1200 μg/ml. At 72 h post-inoculation, the concentrations returned to pre-inoculation values. There was significantly (p = 0.004) less intense response in the control groups; however, a very mild increase of SAA levels was detected due to the stress inevitably caused by the sampling procedure.

scholarly journals A Rapid Enzyme-Linked Immunosorbent Assay for Serum Amyloid a Using Sequence-Specific Antibodies

1993 ◽  
Vol 30 (3) ◽  
pp. 278-286 ◽  
Author(s):  
Martin-Tino Časl ◽  
Anders Grubb
Keyword(s):  
Immunosorbent Assay ◽  
Serum Amyloid A ◽  
Serum Amyloid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Microtitre Plate ◽  
Amyloid A ◽  
Diagnostic Potential ◽  
Assay Time ◽  
Reliable Marker ◽  
Specific Rabbit

A microtitre plate based enzyme-linked immunosorbent assay for determining the concentration of serum amyloid A (SAA) is described. The method employs easily produced sequence-specific rabbit antibodies and the preferential absorption of SAA to polystyrene, which obviates the use of capture antibodies and allows an assay time of only 3 · 5 h, so that the diagnostic potential of the SAA level as a rapid and reliable marker for inflammation can be fully exploited. The assay has a working concentration range of 0·1–2500 mg/L, which embraces the known biological variation of the SAA concentration. The intra-assay coefficient of variation (CV) for SAA concentrations above 10 mg/L is between 1 · 6 and 3·3% and the inter-assay CV between 3·0 and 4·2%. Recovery of SAA added to serum is from 96 to 102%.

Sign in / Sign up

Export Citation Format

Share Document